Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy HIV-negative Adolescents Living in a TB Endemic Region.
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2017
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacodynamics
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Planned end date changed from 1 Sep 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
- 23 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.